Want to see KR:302440 full AI Analyst Report?

SK bioscience Co.,Ltd. (302440) Price & Analysis

1 Followers

302440 Stock Chart & Stats

$32750.00

$550.00(1.71%)

Oct 30, 2026

―

Day’s Range― - ―

52-Week Range$31,500.00 - $61,300.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)61.27K

Market Cap

₩2.57T

Enterprise Value$2.76T

Total Cash (Recent Filing)₩832.60B

Total Debt (Recent Filing)₩543.37B

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Nov 05, 2026

EPS Estimate

-387.97

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1066.27

Shares Outstanding78,456,550

10 Day Avg. Volume74,925

30 Day Avg. Volume61,268

Financial Highlights & Ratios

PEG Ratio-25.96

Price to Book (P/B)2.11

Price to Sales (P/S)5.79

P/FCF Ratio-46.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-882.32

Revenue Forecast (FY)₩690.59B

Bulls Say, Bears Say

Bulls Say

Integrated Vaccine CapabilitiesAn integrated presence across vaccine R&D, clinical development, manufacturing and distribution gives the company control across the product lifecycle. Its mix of routine, preventive and pandemic-response vaccines can support multiple demand channels and preserve strategic relevance beyond one product.

Strong Equity BaseThe sizable equity base provides a meaningful buffer against operating volatility and supports continued investment in vaccine development and production. This capital cushion can improve resilience over the next several quarters, even while profitability and cash generation remain under pressure.

Moderate LeverageModerate leverage reduces the balance-sheet burden relative to a heavily indebted biotechnology business and preserves more financial flexibility. Although returns are currently weak, the existing capital structure offers greater capacity to withstand losses and fund strategic priorities than high leverage would.

Bears Say

Severe Revenue ContractionThe extreme TTM revenue contraction indicates that recent commercial performance has weakened materially rather than merely fluctuating around a stable base. Sustained losses following earlier profitability raise execution risk and make it harder to support development spending, fixed costs and durable earnings recovery.

Deeply Negative Free Cash FlowDeeply negative free cash flow shows that investment and other outflows are not currently supported by operating inflows. Persistent cash burn can increase funding needs, restrict strategic flexibility and make the business more vulnerable if weak revenue and profitability continue over the coming quarters.

Weak Returns And Rising LeverageAlthough leverage remains moderate, its increase alongside negative returns on equity signals that the capital structure is not presently producing adequate profits. If operating performance stays weak, higher leverage may add financial pressure without generating the returns needed to rebuild earnings power.

SK bioscience Co.,Ltd. News

SK bioscience to Brief Analysts on Q3 Results and Business Outlook

An announcement from SK bioscience Co.,Ltd. ( ($KR:302440) ) is now available. SK bioscience Co., Ltd. will hold...

6d ago

302440 FAQ

What was SK bioscience Co.,Ltd.’s price range in the past 12 months?

SK bioscience Co.,Ltd. lowest stock price was $31500.00 and its highest was $61300.00 in the past 12 months.

What is SK bioscience Co.,Ltd.’s market cap?

SK bioscience Co.,Ltd.’s market cap is ₩2.57T.

When is SK bioscience Co.,Ltd.’s upcoming earnings report date?

SK bioscience Co.,Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.

How were SK bioscience Co.,Ltd.’s earnings last quarter?

SK bioscience Co.,Ltd. released its earnings results on Aug 10, 2026. The company reported -$179.59 earnings per share for the quarter, beating the consensus estimate of -$340.68 by $161.09.

Is SK bioscience Co.,Ltd. overvalued?

According to Wall Street analysts SK bioscience Co.,Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SK bioscience Co.,Ltd. pay dividends?

SK bioscience Co.,Ltd. does not currently pay dividends.

What is SK bioscience Co.,Ltd.’s EPS estimate?

SK bioscience Co.,Ltd.’s EPS estimate is -387.97.

How many shares outstanding does SK bioscience Co.,Ltd. have?

SK bioscience Co.,Ltd. has 78,456,550 shares outstanding.

What happened to SK bioscience Co.,Ltd.’s price movement after its last earnings report?

SK bioscience Co.,Ltd. reported an EPS of -$179.59 in its last earnings report, beating expectations of -$340.68. Following the earnings report the stock price went up 1.085%.

Which hedge fund is a major shareholder of SK bioscience Co.,Ltd.?

Currently, no hedge funds are holding shares in KR:302440

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SK bioscience Co.,Ltd.

SK bioscience Co.,Ltd. is a pharmaceutical firm focused on the discovery, development, production, and worldwide commercialization of vaccines and other biopharmaceutical products. Its current range of marketed vaccines includes Skycellflu, a cell-cultured influenza vaccine, along with its pre-filled syringe version, Skycellflu 4-ga. The company also provides pneumococcal vaccines for both adults and children, Skyzoster for shingles, and Sky Baricella, designed to prevent chickenpox in pediatric patients. Beyond its existing portfolio, SK bioscience maintains an active research and development pipeline. Several candidates have completed Phase 2 clinical trials, including an oral rotavirus vaccine, a cervical cancer vaccine, and a low-cost pneumococcal vaccine. A distinct rotavirus vaccine is currently in Phase 3 trials in Africa, while a next-generation pneumococcal vaccine is undergoing Phase 2 trials in the United States. Other projects in development include a typhoid conjugate vaccine and a COVID-19 vaccine, which is progressing through Phase 1 and Phase 1/2 clinical studies. The company was established in 2018 and is headquartered in Seongnam-si, South Korea.